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Abstract The unc-47 locus of Caenorhabditis elegans has been 
suggested to encode a synaptic vesicle GABA transporter. Here 
we used hydropathy plot analysis to identify a candidate vesicular 
GABA transporter in genomic sequences derived from a region of 
the physical map comprising unc-47. A mouse homologue was 
identified and cloned from EST database information. In situ 
hybridization in rat brain revealed codistribution with both 
GABAergic and glycinergic neuronal markers. Moreover, 
expression in COS-7 and PC12 cells induced an intracellular, 
glycine-sensitive GABA uptake activity. These observations, 
consistent with previous data on GABA and glycine uptake by 
synaptic vesicles, demonstrate that the mouse clone encodes a 
vesicular inhibitory amino acid transporter. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Before their exocytotic release for neurotransmission, non-
peptide neurotransmitters are loaded into synaptic vesicles by 
vesicular transporters driven by a H+-ATPase [1,2]. Studies 
on isolated secretory vesicles have identified independent up-
take activities for monoamines (catecholamines, serotonin, 
histamine), acetylcholine, glutamate, GABA and glycine, 
and ATP. The transporters responsible for the first two activ-
ities have been recently identified. Two isoforms of the mam-
malian monoamine transporter, VMAT1 and VMAT2, were 
characterized by cDNA expression cloning [3,4]. These iso-
forms, derived from distinct genes, share about 60% amino 
acid identity. Thereafter, a highly homologous protein was 
revealed by cDNA cloning and sequencing of the Caenorhab-
ditis elegans unc-17 gene [5]. Since this protein was shown to 
be localized to cholinergic synaptic vesicles, it was concluded 
that the unc-17 gene encodes the vesicular acetylcholine trans-
porter. Cloning and expression of homologous vertebrate pro-
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teins firmly established this conclusion [6,7]. These three re-
lated transporters contain ~500 amino acids, and possess 12 
putative transmembrane domains (TMs) with a large, intra-
vesicular 'loop' between TM1 and TM2 according to current 
topological models. 
Although a majority of central nervous system synapses use 
amino acids as transmitters, the corresponding vesicular trans-
porters have not yet been characterized. Here we report the 
cDNA cloning and expression of a vesicular transporter for 
GABA and glycine, based on recent genetic studies in C. 
elegans. In this animal, the reciprocal inhibition of opposing 
body muscles is ensured by GABAergic neurons. The selective 
destruction of these neurons with a laser microbeam was re-
cently shown to induce a 'shrinker' behaviour [8] and, in a 
related study [9], several mutants displaying a 'shrinker' phe-
notype were found to be selectively impaired in GABAergic 
transmission. Interestingly, the absence of defects in GABA 
synthesis or GABA postsynaptic sensitivity in two mutants, 
unc-46 and unc-47, led to the suggestion that the unc-46 or 
unc-47 genes might encode the vesicular GABA transporter 
[9]. Since the defects observed in unc-47 animals were more 
severe and unambiguously presynaptic, we investigated this 
hypothesis for the unc-47 gene. 
2. Materials and methods 
2.1. Bioinformatics 
An integrated genetic and physical map of C. elegans (ACeDB) is 
accessible at the WWW site: http://probe.nalusda.gov. The positive 
clones of loci stP127 and unc-69, cosmids RW#L127 and C46D2 
respectively, were used to select the following set of sequenced cos-
mids: M04D8, T16G12, T16H12, ZK1128, K08E5, T20G5, R01H10, 
K10G9, and T07A5. These cosmids overlap, except T20G5 and 
R01H10 which are separated by a gap of about 40 kb. The proteins 
predicted from the cosmid sequences are accessible in Genbank or 
equivalent databases. Hydropathy profiles [10] were plotted using 
the DNA Strider 1.2 software, with a window size of 11. Homology 
searches in gene databases were performed using BLAST [11]. The 
significance of the highest scores was assessed further by global pair-
wise alignment using BESTFIT (GCG software package). Fifty align-
ments of randomized sequences were performed as negative controls. 
2.2. Cloning of the mouse VIA A T cDNA 
The mouse and human I.M.A.G.E. cDNA clones [12] correspond-
ing to ESTs [13] W64201 (ID #385606) and H23502 (ID #52553), 
respectively, were obtained from GenomeSystems. The mouse clone 
contains a short cDNA fragment (406 bp). An EST 'bridging' strat-
egy, using PCR on mouse brain Marathon-Ready cDNA with Ad-
vantage-HF polymerase mix (Clontech), was developed to isolate lon-
ger cDNAs. Amplifications using primers derived from the three non-
overlapping mouse ESTs W64201, R75019 and R75020 indicated that 
they all derived from a single mRNA species. A 1277 bp partial 
cDNA was amplified using the primers 5'-GAATTGAAC-
TAGGGGCGCAGAAG, derived from EST W64201, and 5'-CCA-
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97)01279-9 
178 C. Sagne et al.lFEBS Letters 417 (1997) 177-183 
CATCGAAGAAGACCTGGTGC, derived from EST R75019. The 
PCR product was characterized by TOPO TA Cloning (Invitrogen) 
and automated sequencing (ABI). This product lacks both 5' and 3' 
ends of the coding sequence. To recover the 3' end, we followed the 
same bridging strategy: the human clone was sequenced, providing a 
733 bp 3' untranslated sequence that was used as a query sequence for 
a second-round homology searching and led to the identification of a 
novel mouse EST, AA028280. This EST lacks coding sequence and 
was thus not identified in the first round (done with the T20G5.6 
amino acid sequence as a query). PCR with primers 5'-CATCT-
TATTCACCACGAGCACACCACAC, derived from AA028280, 
and 5'-ACATCCTGGTCATCGCTTACTGTCTC, derived from 
R75019, amplified a 1018 bp product that perfectly matched the pre-
vious clone in a 652 bp overlap and extended 283 bp downstream the 
STOP codon. 5'-RACE [14] with the mVIAAT antisense primer 5'-
GCATTTGTCACGTTCCAGCCCGCTTCC and the Marathon 
Adaptor Primer 1 was used to recover the 5' end. Four consistent 
independent clones, extending up to 44 bp upstream the first in-phase 
ATG, were obtained. 
Each base of the reassembled mVIAAT coding sequence was deter-
mined by sequencing both strands of 2 to 4 independent PCR clones, 
in order to discard possible PCR artefacts (a single point mutation 
was found). It has to be noted that the first 10 bases of EST W64201 
mismatches the coding sequence due to a cloning artefact of the 
I.M.A.G.E. clone #385606. A full-length cDNA clone was con-
structed by ligating the longest 5'-RACE product and the 3'-RT-
PCR product to the 1277 bp partial cDNA, at restriction sites Dralll 
and AflU, respectively. The full-length mVIAAT cDNA was sub-
cloned into the expression vector pcDNA3 (Invitrogen). 
2.3. In situ hybridization 
Single strand, [35S]UTP-labelled cRNA antisense probes were syn-
thesized with Ampliscribe kits (Epicentre Technology). The following 
plasmids were used as templates for the synthesis of the probes: (i) a 
full-length rat GAD67 cDNA in pSPT18 (a gift of J.F. Julien [15]), (ii) 
a RT-PCR product from mouse brain encoding the 323 C-terminal 
amino acids of GLYT2 [16], cloned in pCRII (Invitrogen) and (iii) for 
mVIAAT, the mouse I.M.A.G.E. clone #385606 in pT7T3D-PAC. 
The templates (50 ng) were linearized with PvuW (GAD67) or Xhol 
(GLYT2 and mVIAAT), and used with SP6 (GAD67 and GLYT2) or 
T3 polymerase (mVIAAT). Cryostat parasagittal or coronal rat brain 
sections (10 um) were mounted on slides, fixed in 4% formaldehyde 
and hybridized overnight at 60°C with the labelled riboprobes (2 X 106 
dpm in 50 |il). Slides were treated with RNAase A, washed in 
0.1 XSSC buffer (30 mM NaCl, 3 mM sodium citrate) at 55°C, dried 
and apposed to (3 max Hyperfilms (Amersham) for 5 days. For ob-
servations at the cellular level, sections were dipped into emulsion 
(LM1, Amersham), exposed for 8 days and photographed under 
dark-field or bright-field light. 
2.4. Expression in COS-7 and PCI2 cells 
COS-7 cells were grown under 5% C02 in glucose rich Dulbecco's 
Modified Eagle Medium supplemented with 7.5% foetal bovine serum 
(GIBCO BRL). PC12 cells were cultured in RPMI 1640 medium 
supplemented with 2 mM L-glutamine and 7% Supreme serum (Bio-
Products). Cells (106 and 5xl06 for COS-7 and PC12, respectively) 
were transfected by electroporation with both pcDNA3-mVIAAT and 
a plasmid encoding a plasma membrane transporter of GABA (rat 
GAT1 in pcDNAl, a gift of N. Nelson [17]) or glycine (human 
GLYTlb in pRcCMV [18]). Negative controls were done by replacing 
the VIAAT plasmid by a pcDNA3 vector bearing no insert or a 
cDNA for the bovine vesicular monoamine transporter VMAT2 
[19]. The transfected cells were divided in 12 aliquots and cultured 
in 24-well (15 mm diameter) culture plates. Two or three days after 
transfection, GABA or glycine uptake by intact adherent cells was 
assayed as follows. The culture wells were washed twice with 0.5 ml 
uptake buffer (5 mM Tris/HEPES, pH 7.5, 140 mM NaCl, 5.4 mM 
KC1, 0.8 mM MgS04, 1 mM ascorbic acid, 5 mM D-glucose). Cells 
were then incubated for 10 min at room temperature in 0.2 ml uptake 
buffer supplemented with 30 nM [3H]GABA (84 Ci/mmol; Amer-
sham) or 300 nM [3H]glycine (16 Ci/mmol; Amersham). The reaction 
was stopped by two brief washings with 0.5 ml of ice-cold uptake 
buffer. The radioactivity accumulated in the wells was recovered in 
0.2 ml of 0.1 N NaOH and counted by liquid scintillation in Ready 
Protein"1" (Beckman). 
3. Results 
We used a positional cloning strategy to identify a vesicular 
GABA transporter candidate from nematode genomic sequen-
ces [20]. The nearest neighbouring cloned loci of unc-47 on the 
current genetic map III of C. elegans, namely stP127 and unc-
69, were used to define a region of the physical map compris-
ing unc-47. Nearly 90% of this region was sequenced at the 
time of our search. The known sequence, encompassing 280 
kb, was distributed on two sets of overlapping cosmids sepa-
rated by a 40 kb gap. In order to select transporter candi-
dates, we analyzed the hydropathy plots of the 60 proteins 
predicted from this sequence. Nine hypothetical proteins had 
at least 6 maxima reaching a hydropathic index of 2 or more. 
Considering the size range of most known ion-coupled trans-
porters, 5 proteins of less than 400 or more than 900 amino 
acids were not analyzed further. Homology searching showed 
that three of the four remaining candidates shared about 40% 
overall amino acid identity with functionally characterized 
mammalian transporters: the Na+/dicarboxylate cotransport-
er [21], for hypothetical protein K08E5.2, and the brain-spe-
cific Na+/phosphate cotransporter [22], for both K10G9.1 and 
T07A5.3. This value of 40% was considered as suggestive of 
functional similarity based on pairwise alignments of func-
tionally characterized orthologous proteins, such as the rat 
and nematode vesicular acetylcholine transporter [6,23]. The 
last candidate, T20G5.6, showed no homology with function-
ally known proteins and was thus considered as the leading 
candidate for the unc-47 gene product. 
We then performed a homology search for T20G5.6 in the 
EST division of Genbank [24]. This led to the identification of 
four ESTs from mouse or human brain, sharing 40-50% iden-
tity with T20G5.6 in 60-90 amino acid stretches: W64201, 
R75019, R75020 and H23502. The clones corresponding to 
ESTs W64201 (from mouse) and H23502 (from human) 
were available from the I.M.A.G.E. Consortium [12]. Since 
both of them are partial clones, a combination of RT-PCR 
and 5'-RACE [14] was used to recover a full-length coding 
sequence from mouse brain (see Section 2.2). As shown in Fig. 
la, the amino acid sequence deduced from the mouse cDNA 
is 38% identical to the nematode sequence for T20G5.6. Since 
in situ hybridization and expression studies indicate that the 
mouse protein is a vesicular transporter of GABA and glycine 
(see below), the protein will be designated as mVIAAT, for 
'mouse vesicular inhibitory amino acid transporter', to refer 
to the usual role of GABA and glycine in neurotransmission. 
Hydropathy plots [10] of mVIAAT and T20G5.6, shown in 
Fig. 1. Structure of mVIAAT. a: Optimal alignment of the mouse VIAAT and nematode T20G5.6 sequences. The alignment was determined 
using BESTFIT. The hydrophobic core of putative transmembrane domains are lined above the mouse sequence and numbered. Since the sec-
ond in-frame ATG codon of the mouse sequence has a better context for the initiation of translation (GCC AGG ATG G) than the first one 
(AGC GGC ATG T), the mouse polypeptide may possibly begin at residue M4. b: Hydropathy plot of the mouse sequence, c: Topological 
model of mVIAAT. 
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Fig. 2. Regional distribution of the VIAAT mRNA in rat brain. The distribution of the VIAAT mRNA (b and e) is compared with those of 
GAD67 (a and d) and GLYT2 (c and f) in parasagittal (a, b and c) and coronal (d, e and f) sections. Arrows in b, c, e and f point at glyciner-
gic nuclei. A diagram depicts the main structures for each section. Abbreviations: Ace, nucleus accumbens; Cb, cerebellum; CPu, caudate puta-
men; Cx, cortex; Hip, hippocampus; IC, inferior colliculus; LSO, lateral superior olivary nucleus; MPVO, medioventral periolivary nucleus; 
OB, olfactory bulb; Rt, reticular thalamic nucleus; SC, superior colliculus; SNR, substantia nigra pars reticulata. 
Fig. lb for the mouse sequence, predict the existence of 10 
transmembrane domains (TMs), with a large, hydrophilic N-
terminal domain (Fig. lc). The latter domain lacks a signal 
peptide and, due to its size, may fold before the first TM is 
synthesized and inserted in the reticulum membrane. The N-
terminus is thus assumed to be cytosolic. A consequence of 
this topological model is that mVIAAT may not be N-glyco-
sylated, since the first putative glycosylation site (N98) is cy-
tosolic and the second one (N315), albeit luminal, is too close 
to TM6 to reach the active site of oligosaccharide transferase 
[25]. Eight protein kinase C or casein kinase II consensus sites 
are present in the mouse sequence, among which three, 
present in the N-terminal domain (Til , S39 and T91), might 
have a biological significance. The other sites are luminal or 
close to the TMs, and thus should not be accessible to protein 
kinases. An interesting feature shown by the alignment (Fig. 
la) is the presence of three conserved, charged residues in 
TM2 (El87), TM6 (K325) and TM7 (K363), which might 
prove critical for the activity of the proteins. 
Neither the mouse VIAAT nor the nematode protein 
T20G5.6 have homology with functionally characterized pro-
teins. In particular, no significant homology could be detected 
with the vesicular monoamine or acetylcholine transporters 
(Table 1). However, homology searching allowed the detec-
tion of a weak similarity of mVIAAT with several 'orphan' 
proteins predicted from genomic sequences. The results of 
Table 1 
Homologies of mVIAAT 
Species Protein Status % Identity Quality score Average quality score 
after 50 randomizations (± S.D.) 
Caenorhabditis elegans 
Arabidopsis thaliana 
Saccharomyces cerevisiae 
Saccharomyces cerevisiae 
Saccharomyces cerevisiae 
Rattus norvegicus 
Rattus norvegicus 
T20G5.6 
ATU90439 
YJROOlw 
YNLlOlw 
YEL064c 
rVMAT2 
rVAChT 
hypothetical 
hypothetical 
hypothetical 
hypothetical 
hypothetical 
translated (cDNA) 
translated (cDNA) 
37.6 
27.0 
21.5 
20.2 
20.1 
13.5 
19.0 
352.6 
218.6 
213.1 
221.4 
197.0 
161.9 
163.6 
146.1 ±5.5 
143.815.1 
165.0 ±4.9 
168.3 ±5.4 
148.5 ±4.9 
159.114.6 
162.6 ±5.5 
Results of BESTFIT alignments with mVIAAT are shown. Statistically significant alignments have a quality score above the average score obtained 
with randomized sequences. Proteins predicted from genomic sequences are mentioned as 'hypothetical' and designated by their individual codes, 
except for the A. thaliana protein, which corresponds to an unannotated open reading frame (bases 30749-31990) in the BAC clone T06D20 from 
chromosome II (accession #U90439). Data for the rat vesicular monoamine transporter (rVMAT2; ace. #M97381) and acetylcholine transporter 
(rVAChT; ace. #U09211) are shown for comparison. 
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Fig. 3. Cellular distribution of the VIAAT mRNA in rat brain. Dark-field microphotographs of emulsion-coated sections are shown for the re-
ticular thalamic nucleus (a and b), the cerebellum (c and d) and the lateral superior olive in the brainstem (e, f and g). The slides were labelled 
with probes for the GAD67 (a, c and e), VIAAT (b, d and f) or GLYT2 (g) transcripts. Abbreviations: Rt, reticular thalamic nucleus; p, Pur-
kinje cell layer. Scale bar, 300 urn. 
pairwise global alignments are shown in Table 1 for the five 
highest scores of the BLAST search [11], excluding ESTs. Low 
homologies (20-27% identity) were observed with four plant 
or yeast proteins. A randomization test showed that these 
homologies, which are scattered along the overall alignments 
(not shown), are statistically significant (Table 1). The biolog-
ical significance of these alignments is further supported by 
the fact that these orphan proteins are also homologous to 
one another; for example, the Arabidopsis thaliana protein is 
27% identical to the Saccharomyces cerevisiae protein 
YNLlOlw (not shown). These data suggest that mVIAAT, 
its nematode homologue and the distantly related yeast 
and plant proteins may have evolved from a common ances-
tor. 
As a first step to determining the function of VIAAT, we 
characterized the distribution of its cognate mRNA in rat 
Fig. 4. Expression of the mouse VIAAT in PC12 and COS-7 cells. Cells were transfected with the VIAAT or VMAT2 cDNA, as well as with 
the GAT1 and/or GLYTlb cDNAs. [3H]GABA uptake was assayed as described in Section 2.4. Black bars correspond to the addition of 0.2 
mM nipecotic acid (a) or 10 mM glycine (c) to the uptake medium. Data are means ±S.E.M. of 3 to 6 determinations. The asterisk (*) in (c) 
denotes a statistically significant difference with the other bars (P< 0.005; » = 4). 
182 C. Sagne et al.lFEBS Letters 417 (1997) 177-183 
brain by in situ hybridization, and compared it with that of 
markers of GABAergic and glycinergic neurons. We used the 
GAD67 isoform of the GABA biosynthetic enzyme glutamic 
acid decarboxylase as a marker of GABAergic neurons [15,26] 
and the plasma membrane glycine transporter GLYT2 as a 
marker of glycinergic neurons [16,27-29]. The GLYT2 protein 
has been shown recently by electron microscopic immunocy-
tochemistry to be almost exclusively localized in axons and 
terminals of neurons thought to be glycinergic [29]. As shown 
in Fig. 2a, b, d and e, the regional distribution of the VIAAT 
mRNA paralleled that of GAD67 in the olfactory bulb, the 
thalamic reticular nucleus and the cerebellum, as well as in 
more diffusely labelled areas such as the superior and inferior 
colliculi, the caudate-putamen, the hippocampus and the sub-
stantia nigra. However, in the brainstem, the VIAAT mRNA 
appeared concentrated in nuclei of the superior olivary com-
plex, which were not detected with the GAD67 probe but 
were intensely labelled by the GLYT2 probe (Fig. 2c and f, 
arrows). These nuclei are documented as glycinergic [29]. The 
overall intensity observed with the three markers indicated 
that the level of VIAAT transcript is in the same range as 
that of GLYT2, but much lower than that of GAD67. The 
correlation of the mVIAAT mRNA distribution with those of 
GAD67 and GLYT2 was also investigated at the cellular lev-
el. Similar patterns were observed for the VIAAT and GLYT2 
mRNAs in the lateral superior olive (Fig. 3f and g). In known 
GABAergic structures [26], such as the reticular nucleus (Fig. 
3a and b), the inferior colliculus, the hilus of the hippocampal 
dentate gyrus and the olfactory bulb (not shown), similar 
patterns were observed for the VIAAT and GAD67 mRNAs. 
In the cerebellar cortex, the GABAergic Purkinje neurons 
were unambiguously labelled by both the VIAAT and 
GAD67 mRNA probes (Fig. 3c and d, arrowheads). Taken 
together, these observations suggest that VIAAT is selectively 
expressed in both GABAergic and glycinergic neurons of the 
rat brain. 
To examine more directly the function of VIAAT, COS-7 
and PC 12 cells were transiently transfected with both the full-
length mVIAAT clone and a clone for a plasma membrane 
GABA or glycine transporter (GAT1 [17] and GLYTlb [18], 
respectively). [3H]GABA or [3H]glycine uptake by intact cells 
was assayed 2 or 3 days after transfection. As shown in Fig. 
4a and b, GAT1- and VIAAT-transfected cells exhibited an 
increased amount of accumulated [3H]GABA over negative 
controls in which VIAAT was replaced by the vesicular mono-
amine transporter VMAT2 [19]. It should be noted that when 
GAT1 was inhibited by nipecotic acid or replaced by 
GLYTlb, no GABA uptake was observed in VIAAT-trans-
fected cells. This dependence of VIAAT activity on the plasma 
membrane transport of GABA suggests that VIAAT uptake 
occurs in an intracellular compartment. To test the ability of 
VIAAT to recognize glycine, COS-7 cells were transfected 
with the three plasmids GAT1, GLYTlb and VIAAT, and 
unlabelled glycine was added to the uptake medium (Fig. 
4c). Glycine at 10 mM fully inhibited the VIAAT-mediated 
[3H]GABA uptake without affecting the GAT 1-mediated one. 
Moreover, we reproducibly observed a small but significant 
increase in [3H]glycine uptake (9.5% ± 1 % S.D.) when PC12 
cells transfected by both GLYTlb and VIAAT were com-
pared with controls transfected by GLYTlb alone (6 trans-
fections). We thus conclude that VIAAT cDNA encodes a 
GABA and glycine transporter. 
4. Discussion 
In this study, we describe the cDNA cloning and expression 
of a mouse GABA and glycine transporter, designated VI-
AAT, based on the identification of candidate mouse and 
nematode vesicular GABA transporters by database screen-
ing. The characteristics displayed by VIAAT are consistent 
with biochemical data on GABA and glycine transport into 
synaptic vesicles. GABA and glycine are taken up by isolated 
rat brain vesicles in an ATP-dependent manner [30-32]. Com-
petition experiments [33,34], as well as the fact that the ratio 
of GABA to glycine uptake was similar in vesicle preparations 
of predominantly GABAergic or glycinergic origin [35], have 
led to the conclusion that these two transmitters are taken up 
by similar, if not identical, transporters (but see [32]). Mor-
phological studies have even suggested that some GABAergic 
terminals might co-store and co-release glycine [36,37]. In 
contrast, GABA and glycine are highly discriminated by their 
plasma membrane transporters (for example, see [16]). There-
fore, the GABA- and glycine-specific profile of both in situ 
hybridization and amino acid uptake data strongly supports 
the proposal that VIAAT is a vesicular transporter. This con-
clusion is strengthened by the likely intracellular localization 
of VIAAT in COS-7 and PC12 cells. 
The identification of VIAAT as a vesicular GABA and 
glycine transporter means that the putative protein T20G5.6 
is likely to represent the nematode homologue. We may also 
predict with some confidence that, as initially suggested by 
our database screening, T20G5.6 corresponds to the unc-47 
gene product. Although genetic experiments are needed to 
confirm this last conclusion, the successful identification of 
VIAAT already demonstrates the considerable time- and 
cost-saving benefits of genome databases. Database screening 
allows one to go rapidly from an hypothesis on what a gene 
product might do to what the protein sequence might be, 
thereby greatly facilitating experimental testing. A simple hy-
dropathy profile criterion was used here to extract 4 candidate 
transporters from a ~ 300 kb genomic sequence. Other struc-
tural features, such as ligand-binding or leucine zipper motifs, 
etc., based on knowledge of the presumed protein family, 
might prove useful in identifying other genes. In addition, 
the easy access to sequences from other organisms by homol-
ogy searching facilitates the design of the most efficient exper-
imental test. 
The molecular characterization of VIAAT should facilitate 
anatomical and physiological studies on GABAergic and gly-
cinergic transmission. In particular, the availability of probes 
for both the vesicular and plasma membrane transporters will 
help to determine the relative contributions of these trans-
porters in the modulation of GABA and glycine signalling. 
On the other hand, the presence of VIAAT at both GABAer-
gic and glycinergic terminals, as suggested by our in situ hy-
bridization data, may provide a means to generally survey 
inhibitory neuron plasticity or degeneration. In this context, 
the search for VIAAT inhibitors using heterologous expres-
sion systems might find potential diagnostic applications in 
the development of in vivo imaging radioligands. 
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